Livzon Pharmaceutical (000513) Q3 2026 earnings summary

Executive summary

• Q3 2026 revenue fell 18.44% YoY to RMB2.320bn; net profit attributable to shareholders declined 24.76% to RMB355.9m. YTD revenue and attributable net profit fell 19.71% and 26.57%, respectively.

• YTD operating cash flow remained strong at RMB2.492bn, down 1.33% YoY.

Financial highlights

• Q3 revenue was RMB2.320bn, down 18.44% YoY; YTD revenue was RMB7.319bn, down 19.71%.

• Q3 net profit attributable to shareholders was RMB355.9m, down 24.76%; YTD was RMB1.288bn, down 26.57%.

• Excluding non-recurring items, attributable net profit was RMB370.2m in Q3, down 18.39% YoY, and RMB1.260bn YTD, down 26.38%.

• YTD operating profit was RMB1.843bn versus RMB2.511bn; net profit was RMB1.552bn versus RMB2.130bn.

Key financial ratios and metrics

• Basic and diluted EPS were RMB0.40 in Q3, down 23.08% YoY; YTD EPS was RMB1.45, down 26.02%.

• Weighted average ROE was 2.61% for Q3, down 0.8 percentage points, and 9.22% YTD, down 3.27 percentage points.

• Period-end total assets were RMB23.246bn, down 3.08% from year-end; equity attributable to shareholders was RMB13.019bn, down 6.26%.